Cigna (Commercial)

How Cigna (Commercial) approaches GLP-1 coverage

Cigna administers both fully-insured commercial policies and ASO self-funded employer plans, with Express Scripts (ESI) serving as the pharmacy benefit manager and gatekeeper of formulary tier and prior authorization rules. For type 2 diabetes indications, GLP-1 receptor agonists such as Ozempic, Mounjaro, and Rybelsus may be considered for coverage when documentation supports a T2D diagnosis and step therapy criteria are met; coverage details should be verified against your specific plan and the current year formulary. For weight-loss GLP-1s (Wegovy, Zepbound, Saxenda), coverage is highly employer-dependent. Many self-funded employers explicitly carve out anti-obesity medications, while others include them with BMI thresholds, lifestyle-program participation, and prior authorization. Because ACA essential health benefits do not require anti-obesity drug coverage, exclusions are common. Members should pull their plan's prescription drug rider, the Express Scripts formulary applicable to their group, and any utilization management documents to confirm benefits before relying on coverage.

Statutory and structural notes

Commercial coverage is governed by ERISA for self-funded ASO plans and by state insurance law for fully-insured plans; neither is bound by the Medicare Part D weight-loss exclusion at SSA §1860D-2(e)(2)(A) (MMA 2003). The ACA (42 U.S.C. §18022) does not list anti-obesity drugs among essential health benefits, so coverage is discretionary. Mental Health Parity (MHPAEA) and state mandates may indirectly affect related counseling benefits.

Typically considered for coverage

The list below reflects general patterns observed across Cigna (Commercial)plan documents. Coverage for any specific drug, dose, or indication must be confirmed against your own plan's current formulary and medical policy.

• Ozempic (semaglutide) for type 2 diabetes may be considered for coverage; verify with your specific plan and current formulary
• Mounjaro (tirzepatide) for type 2 diabetes may be considered for coverage; verify with your specific plan and current formulary
• Rybelsus (oral semaglutide) for type 2 diabetes may be considered for coverage; verify with your specific plan and current formulary
• Trulicity (dulaglutide) for type 2 diabetes may be considered for coverage; verify with your specific plan and current formulary
• Wegovy (semaglutide) for chronic weight management or CVD risk reduction in adults with established cardiovascular disease may be considered for coverage on plans that include an anti-obesity rider; verify with your specific plan and current formulary
• Zepbound (tirzepatide) for chronic weight management or moderate-to-severe obstructive sleep apnea in adults with obesity may be considered for coverage on plans that include the relevant rider; verify with your specific plan and current formulary
• Saxenda (liraglutide) for chronic weight management may be considered for coverage when an anti-obesity benefit is included; verify with your specific plan and current formulary

Typically excluded

• Compounded semaglutide and tirzepatide — not FDA-approved as finished products and routinely excluded from Cigna/Express Scripts commercial benefits
• Anti-obesity medications under employer groups that have elected an explicit weight-loss drug carve-out
• GLP-1s prescribed off-label for cosmetic weight loss without a qualifying BMI or comorbidity diagnosis
• Drugs obtained from non-network or international pharmacies outside the Express Scripts network
• Quantity dispensed beyond formulary day-supply limits or maximum dose thresholds

Prior authorization

Prior authorization is commonly required for GLP-1 medications under Cigna (Commercial) plans. Your prescriber typically submits a PA form with diagnosis codes, lab results (e.g., A1c for T2D, BMI for weight management), documented prior therapy attempts, and clinical justification.

Appeal strategy if denied

Cigna appeals follow a two-level internal review through myCigna, then an external IRO review under state or ERISA rules. Submit chart notes, A1c/BMI history, prior medication trials, and FDA-label indication evidence. Express Scripts handles the pharmacy PA; cite the SELECT trial for Wegovy CVD or SURMOUNT-OSA for Zepbound when applicable.

GLP1Zoom is not an insurance company, broker, or health plan. We summarize general payer patterns from public plan documents and statute to help you ask the right questions. Always verify current coverage with your plan's member services. Full disclaimer.